ARASENS 试验中转移性激素敏感性前列腺癌患者的质量调整无毒性生存分析
ARASENS 试验的 Q-TWiST 分析比较达罗他胺三联疗法与安慰剂二联疗法在转移性激素敏感性前列腺癌中的质量调整生存。达罗他胺组获得额外 6.3 个月 Q-TWiST(p < 0.001),相对增益 16.0%,主要驱动于无毒性生存时间延长和疾病进展时间减少,但毒性时间增加。
要点
- 达罗他胺三联较安慰剂二联增加 6.3 个月 Q-TWiST(p < 0.001),相对增益 16.0%。
- TWiST 均值 17.6 vs 10.9 个月,REL 2.4 vs 8.7 个月,TOX 17.2 vs 11.3 个月。
- Q-TWiST 增益具明确临床重要性,支持以患者为中心的疗效-耐受性权衡决策。
核心结论
- 达罗他胺三联疗法相比安慰剂二联在转移性激素敏感性前列腺癌中提供更长的无毒性生存获益,Q-TWiST 增益具明确临床重要性。
研究设计与样本
- 基于 ARASENS 试验的 Q-TWiST 分析,采用 53 个月限制均值法,依据 3/4 级不良事件、转移性去势抵抗性前列腺癌时间和总生存数据估计各健康状态时间。
主要发现
- 达罗他胺组较安慰剂组获得额外 6.3 个月 Q-TWiST(p < 0.001)。
- TWiST 均值达罗他胺组 17.6 个月 vs 安慰剂组 10.9 个月。
- REL 达罗他胺组 2.4 个月 vs 安慰剂组 8.7 个月。
- 53 个月时 TOX 达罗他胺组 17.2 个月 vs 安慰剂组 11.3 个月。
- 相对 Q-TWiST 增益为 16.0%,属明确临床重要。
临床怎么用
- Q-TWiST 结果可用于评估达罗他胺三联疗法的疗效-耐受性平衡,辅助以患者为中心的临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To identify patients likely to benefit from intensified darolutamide treatment while minimizing adverse events (AEs), this analysis applied quality-adjusted time without symptoms or toxicity (Q-TWiST) to evaluate quality-adjusted survival in metastatic hormone-sensitive prostate cancer in ARASENS, comparing triplet therapy (darolutamide + androgen deprivation therapy [ADT] + docetaxel) with placebo doublet therapy (ADT + docetaxel). METHODS: Time with toxicity (TOX; with grade 3/4 symptoms/toxic effects), time without symptoms or toxicity (TWiST), and time in relapse/disease progression (REL) were estimated using 53-month restricted means based on grade 3/4 AEs, time to metastatic castration-resistant prostate cancer, and overall survival ARASENS data. Q-TWiST was calculated as the utility-weighted sum of time spent in each health state per treatment arm. RESULTS: Patients gained an additional 6.3 months of Q-TWiST with darolutamide versus placebo (p < 0.001) driven by increased TWiST (mean 17.6 months vs 10.9 months), and decreased REL (2.4 months vs 8.7 months). Longer treatment resulted in more TOX (17.2 months vs 11.3 months) at 53 months. Partitioned Kaplan-Meier survival curves showed sustained TWiST with darolutamide versus placebo over 53 months. Relative Q-TWiST gain was 16.0% (clearly clinically important). CONCLUSION: Darolutamide triplet therapy offers longer survival benefits without symptoms or toxicity versus placebo, aiding evaluation of efficacy-tolerability balance and supporting patient-centered decision-making.
引用
- Maiorano BA, Smith MR, Hussain M, et al. Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer from the ARASENS trial. Eur J Cancer. 2026. PMID: 42892235. doi:10.1016/j.ejca.2026.117764
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。